US Diabetes Devices Market 2024–2033

Reports Description

US Diabetes Devices Market was valued at USD 6.8 Billion in 2024 and is expected to reach USD 19.8 Billion by 2033, at a CAGR of 7.3% during the forecast period 2024 – 2033.

Diabetes devices encompass a wide range of tools and technologies designed to help individuals manage their diabetes effectively. These devices include blood glucose meters, continuous glucose monitoring (CGM) systems, insulin pumps, insulin pens, and insulin syringes.

US Diabetes Devices Market: Growth Factors

Growing prevalence of diabetes

The growing prevalence of diabetes in the United States has been a key driver for the expansion of the diabetes device market. As the incidence of diabetes continues to rise, fuelled by factors such as sedentary lifestyles, poor dietary habits, and an aging population, there has been an increased demand for innovative technologies to manage the condition effectively.

Diabetes devices encompass a wide range of products including insulin delivery systems, continuous glucose monitoring (CGM) devices, insulin pumps, and other related accessories. These devices offer patients with diabetes greater convenience, precision, and control over their blood sugar levels, thereby improving their overall quality of life.

Additionally, advancements in technology have led to the development of more user-friendly and integrated devices, which appeal to a broader demographic of patients. Moreover, the emphasis on early detection and proactive management of diabetes has spurred investments in research and development, resulting in the introduction of newer and more advanced devices into the market.

Consequently, the US diabetes device market has experienced significant growth, with manufacturers focusing on innovation, accessibility, and affordability to cater to the evolving needs of patients and healthcare providers.

Increase in healthcare expenditure

The increase in healthcare expenditure in the United States has been a significant driver of growth in the diabetes device market. With rising healthcare spending, there’s been a parallel increase in the prevalence of diabetes, a chronic condition that requires ongoing management and monitoring.

This surge in diabetes cases has created a demand for innovative medical devices that assist in both the diagnosis and treatment of the disease. From glucose monitoring systems to insulin delivery devices, technological advancements in diabetes management have become crucial in improving patient outcomes and quality of life.

Moreover, as healthcare spending continues to rise, there’s an emphasis on preventative care and early intervention, driving the adoption of devices that enable proactive management of diabetes, thereby reducing the long-term healthcare burden associated with complications arising from uncontrolled diabetes.

Consequently, the burgeoning healthcare expenditure landscape in the US has not only fostered innovation in diabetes devices but also incentivized investment in research and development, leading to the introduction of more advanced and efficient solutions for diabetes management.

This symbiotic relationship between healthcare expenditure and the diabetes device market underscores the critical role of economic factors in shaping the trajectory of medical innovation and healthcare delivery.

US Diabetes Devices Market: Restraints

High cost of production

The high cost of production poses a significant barrier to the growth of the US diabetes device market. Production costs encompass various expenses incurred in manufacturing, including raw materials, labour, equipment, and regulatory compliance.

In the context of diabetes devices such as insulin pumps, continuous glucose monitors (CGMs), and glucose meters, the intricate technology and specialized components contribute to elevated production expenses. These devices require precision engineering, high-quality materials, and rigorous testing to ensure accuracy, reliability, and safety.

Additionally, the stringent regulatory standards imposed by the Food and Drug Administration (FDA) further increase production costs, as companies must invest in extensive research, development, and clinical trials to meet regulatory requirements.

The cumulative effect of these factors leads to higher prices for diabetes devices, limiting accessibility for patients, particularly those from lower-income backgrounds or without adequate insurance coverage.

Consequently, the affordability gap obstructs market expansion and impedes widespread adoption of advanced diabetes management technologies, exacerbating healthcare disparities and inhibiting innovation in the field.

Addressing the challenge of high production costs requires collaborative efforts from industry stakeholders, policymakers, and healthcare providers to streamline regulatory processes, promote cost-effective manufacturing practices, and incentivize research and development initiatives aimed at enhancing accessibility and affordability of diabetes devices in the US market.

US Diabetes Devices Market: Opportunities

Rise in obesity rates

The rise in obesity rates has been a significant driver of the US diabetes device market due to the strong correlation between obesity and type 2 diabetes. As obesity rates continue to climb, so does the prevalence of type 2 diabetes, a chronic condition characterized by insulin resistance and high blood sugar levels.

This surge in diabetes cases has spurred the demand for diabetes management devices, including glucose monitoring systems, insulin pumps, and continuous glucose monitoring (CGM) devices. These devices play a crucial role in the effective management and control of diabetes, helping patients monitor their blood sugar levels, administer insulin, and make informed lifestyle choices.

With the increasing emphasis on preventive healthcare and the growing awareness of the importance of diabetes management, the market for diabetes devices has experienced substantial growth.

Moreover, technological advancements in diabetes management devices, such as the development of wearable sensors and integration with smartphone apps for real-time data monitoring and analysis, have further fuelled market expansion.

Thus, the intertwined relationship between rising obesity rates and the escalating prevalence of diabetes underscores the pivotal role of diabetes devices in addressing the healthcare challenges posed by these trends in the United States.

US Diabetes Devices Market: Segmentation Analysis

The US Diabetes Devices market is segmented by type, sale channels and end user.  Based on type, the market is classified into blood glucose monitoring devices and insulin delivery devices. Insulin Delivery Devices dominated the market in 2023 with a market share of 58.3% and are expected to keep their dominance during the forecast period 2024-2033.

Insulin delivery devices play a pivotal role in propelling the US diabetes device market due to their critical function in managing diabetes, a chronic condition characterized by high blood sugar levels. These devices, which include insulin pumps, pens, and syringes, offer convenient and precise methods for administering insulin, a hormone essential for regulating blood sugar levels.

The rising prevalence of diabetes in the United States, driven by factors such as sedentary lifestyles and unhealthy dietary habits, has fuelled the demand for insulin delivery devices. Patients increasingly prefer these devices over traditional insulin administration methods like vials and syringes due to their ease of use, portability, and ability to provide accurate dosing.

Moreover, technological advancements have led to the development of smart insulin pumps and pens equipped with features such as continuous glucose monitoring and dose adjustment algorithms, enhancing their effectiveness in managing diabetes.

The growing adoption of these advanced devices by both patients and healthcare providers further drives the expansion of the US diabetes device market, with continuous innovation and product development anticipated to sustain this growth trajectory in the foreseeable future.

Based on sales channel, the market is classified into hospital pharmacies, and retail pharmacies, diabetes clinics, online pharmacies and others. Hospital pharmacies dominated the market in 2023 with a market share of 32.1% and are expected to keep their dominance during the forecast period 2024-2033.

Hospital pharmacies play a crucial role in driving the US diabetes device market due to their pivotal position in the healthcare system. With diabetes being a prevalent and chronic condition requiring continuous management, hospitals serve as key distribution points for diabetes-related devices such as insulin pumps, continuous glucose monitors (CGMs), and insulin pens.

These devices are essential for monitoring blood sugar levels, administering insulin, and managing the disease effectively. Hospital pharmacies not only provide these devices to patients during their hospital stays but also serve as centers for education and training on their use.

Additionally, hospitals often have outpatient clinics where individuals with diabetes receive ongoing care and access to the latest advancements in diabetes management technology. As a result, hospital pharmacies influence the adoption and utilization of diabetes devices by providing access, education, and support, thereby driving growth in the US diabetes device market.

Their role in ensuring patient adherence to treatment regimens and facilitating the transition to home care settings further underscores their significance in shaping the landscape of diabetes management in the United States.

Based on end users, the market is classified into Hospitals and Diagnostic Centers. Hospitals dominated the market in 2023 with a market share of 66.1% and is expected to keep its dominance during the forecast period 2024-2033. Hospitals play a pivotal role in propelling the US diabetes device market through several mechanisms.

Hospitals often serve as hubs for clinical research and innovation, fostering partnerships with medical device companies to develop and test new diabetes technologies. These collaborations not only drive market growth by introducing novel products but also facilitate access to cutting-edge devices for patients through clinical trials and adoption into standard care protocols.

Thirdly, hospitals influence market dynamics through their purchasing power and reimbursement policies. Their procurement decisions and negotiations with device manufacturers can shape product availability, pricing, and market competition.

Moreover, hospitals’ reimbursement policies impact patient access to diabetes devices, influencing adoption rates and market penetration. Overall, hospitals wield considerable influence over the US diabetes device market, driving innovation, shaping market dynamics, and ensuring access to essential technologies for diabetes management.

Report Scope

US Diabetes Devices Market: Recent Developments

• In March 2023, Medtronic announced the launch of its new MiniMed 780G hybrid closed-loop insulin delivery system. The MiniMed 780G system is a combination of an insulin pump and a CGM system that automatically adjusts insulin delivery based on blood glucose levels. The system is designed to help people with type 1 diabetes achieve better glycemic control.

• In February 2023, Dexcom announced the launch of its new Dexcom G7 CGM system. The Dexcom G7 is a smaller, more accurate, and longer-lasting CGM system than previous models. The system is also designed to be more affordable and easier to use.

• In October 2023, Biocon revealed a partnership with Juno Pharmaceuticals, a specialty pharmaceutical firm in Canada. The collaboration aims to commercialize Liraglutide, a drug-device combination designed to treat and manage Type 2 diabetes and obesity within the Canadian market.

List of the prominent players in the US Diabetes Devices Market:

• Medtronic
• Roche
• Johnson & Johnson
• Abbott Laboratories
• Becton Dickinson and Company
• Novo Nordisk
• Dexcom
• Sanofi
• Insulet Corporation
• Ascensia Diabetes Care Holdings AG
• Ypsomed Holding AG
• Eli Lilly and Company
• LifeScan
• Tandem Diabetes Care
• Terumo Corporation
• Arkray
• Senseonics Holdings Inc.
• MicroPort Scientific Corporation
• Nipro Corporation
• Sinocare Inc.
• AgaMatrix Holdings LLC
• Trividia Health Inc.
• Others

These key players are adopting various growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.

The US Diabetes Devices Market is segmented as follows:

By Type

• Blood Glucose Monitoring Devices
• Insulin Delivery Devices

By Sale Channel

• Hospital pharmacies
• Retail Pharmacies
• Diabetes Clinics
• Online Pharmacies
• Others

By End User

• Hospitals
• Diagnostic Center